SkySTAR platform
Merck KGaA and Skyhawk Therapeutics Launch $2B RNA-Targeting Neurology Collaboration
Merck KGaA; Skyhawk Therapeutics; RNA-targeting; SkySTAR platform; neurological disorders; $2 billion collaboration; drug development; milestone payments; royalties
Merck KGaA Forms $2 Billion Neurological Disease Pact with Skyhawk Therapeutics
Merck KGaA; Skyhawk Therapeutics; neurological diseases; RNA splicing; SkySTAR platform; drug discovery; strategic collaboration; milestone payments